Ashvattha Therapeutics

Ashvattha Therapeutics' Innovative Nanomedicine Technology

Ashvattha Therapeutics specializes in developing cutting-edge nanomedicine therapeutics that leverage hydroxyl dendrimer (HD) technology to target activated cells in regions of inflammation. These precision nanomedicines are designed to traverse tissue barriers such as the blood-brain and blood-retinal barriers, ensuring selective uptake by inflamed tissues only. This targeted approach minimizes off-target toxicity and maximizes therapeutic efficacy, making their treatments particularly promising for conditions in ophthalmology, neurology, and inflammatory diseases.

Ashvattha Therapeutics' Clinical Trials and Research

Ashvattha Therapeutics is actively conducting several clinical trials to test the efficacy of their novel nanomedicine treatments. One notable study is the Phase 2 clinical trial of D-4517.2, an anti-angiogenic nanomedicine targeting wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Another significant trial involves OP-801, a PET imaging agent being evaluated in a Phase 1/2 study for its ability to cross the blood-brain barrier and target neuroinflammation in diseases such as ALS, Alzheimer's, multiple sclerosis, and Parkinson's. These trials are crucial for validating the safety and effectiveness of their innovative treatments.

Ashvattha Therapeutics' Product Portfolio

Ashvattha Therapeutics has developed a robust portfolio of precision nanomedicines, including D-4517.2 and OP-101. D-4517.2 targets activated microglia, macrophages, and retinal pigment epithelial cells in the eye, offering a potential first-in-class, at-home therapy for wet AMD and DME. OP-101, or acetylcysteine zidrimer, selectively targets activated macrophages and has shown significant effects in reducing neuroinflammation and inflammatory biomarkers, particularly in severe COVID-19 cases. These products exemplify the company's commitment to addressing unmet medical needs through innovative therapeutic solutions.

Ashvattha Therapeutics' Biomarker Development

In addition to their therapeutic developments, Ashvattha Therapeutics is advancing the field of biomarker development. They are working on a novel biomarker for neuroinflammation that allows for the quantitative study of blood-brain barrier penetration and treatment response to nanomedicines. This biomarker has the potential to revolutionize the understanding and measurement of neuroinflammation, providing critical insights into the efficacy of treatments for neurological disorders and enabling more personalized and effective therapeutic strategies.

Ashvattha Therapeutics' Headquarters and Research Facilities

Ashvattha Therapeutics operates from its headquarters in Redwood City, California, with additional research laboratories located in Baltimore, Maryland. This strategic placement allows the company to leverage the rich biotech ecosystem of Silicon Valley while maintaining close proximity to leading research institutions on the East Coast. Their state-of-the-art facilities are equipped to support extensive research and development activities, furthering their mission to bring innovative nanomedicine therapeutics to market.